Zura Bio Ltd (ZURA): R&D Expense
$42.08M
Year ended 2025-12-31
$58.36M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $42.08M | +72.5% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $24.40M | -44.5% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $44.00M | n/a | 2025-03-25, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | 2025-12-31 | $42.08M | +72.5% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $17.73M | +42.2% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $69.30M | -21.8% |
| Kalaris Therapeutics, Inc. (KLRS) | 2025-12-31 | $30.75M | -31.7% |
| Acumen Pharmaceuticals, Inc. (ABOS) | 2025-12-31 | $104.89M | +11.8% |
| Anavex Life Sciences Corp. (AVXL) | 2025-09-30 | $37.59M | -10.1% |
| Candel Therapeutics, Inc. (CADL) | 2025-12-31 | $30.50M | +57.9% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $1.23M | +4.2% |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | $69.54M | +38.2% |
Compare ZURA, LCTX, HUMA, KLRS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗